Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis

Toxicology and Applied Pharmacology

Volumn 271, Issue 2, 2013, Pages 276-284

  Van Beneden, Katrien ^a   Geers, Caroline ^b   Pauwels, Marina ^a   Mannaerts, Inge ^a   Wissing, Karl M ^b   Van Den Branden, Christiane ^a   Van Grunsven, Leo A ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Adriamycin; Glomerulosclerosis; Histone deacetylase; Proteinuria; Trichostatin A; Valproic acid

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; DOXORUBICIN; HISTONE H3; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FIBROGENESIS; GLOMERULOSCLEROSIS; HISTONE ACETYLATION; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; MOUSE; NEPHRITIS; NONHUMAN; PROTEINURIA; RENAL PROTECTION; THERAPY DELAY;

ADRIAMYCIN; GLOMERULOSCLEROSIS; HISTONE DEACETYLASE; PROTEINURIA; TRICHOSTATIN A; VALPROIC ACID;

ACETYLATION; ANIMALS; DOXORUBICIN; FEMALE; FIBROSIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY; KIDNEY DISEASES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NEUTROPHIL INFILTRATION; RNA, MESSENGER; VALPROIC ACID;

EID: 84880644265     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.05.013     Document Type: Article

References (60)

1. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
2. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 2005, 25:383-397.
3. Bush E.W., McKinsey T.A. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ. Res. 2010, 106:272-284.
4. Chen A., Sheu L.F., Ho Y.S., Lin Y.F., Chou W.Y., Chou T.C., Lee W.H. Experimental focal segmental glomerulosclerosis in mice. Nephron 1998, 78:440-452.
5. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
6. Chen L.F., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002, 21:6539-6548.
7. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
8. Christensen D.P., Dahllof M., Lundh M., Rasmussen D.N., Nielsen M.D., Billestrup N., Grunnet L.G., Mandrup-Poulsen T. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 2011, 17:378-390.
9. Chugh S.S., Clement L.C., Mace C. New insights into human minimal change disease: lessons from animal models. Am. J. Kidney Dis. 2012, 59:284-292.
10. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370:737-749.
11. Desai V.G., Herman E.H., Moland C.L., Branham W.S., Lewis S.M., Davis K.J., George N.I., Lee T., Kerr S., Fuscoe J.C. Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F(1) mouse model. Toxicol. Appl. Pharmacol. 2013, 266(1):109-121.
12. Freidkin I., Herman M., Tobar A., Chagnac A., Ori Y., Korzets A., Gafter U. Effects of histone deacetylase inhibitors on rat mesangial cells. Am. J. Physiol. Renal Physiol. 2010, 298:F426-F434.
13. Fujimura T., Yamagishi S., Ueda S., Fukami K., Shibata R., Matsumoto Y., Kaida Y., Hayashida A., Koike K., Matsui T., Nakamura K., Okuda S. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol. Dial. Transplant. 2009, 24:1397-1406.
14. Ghizzoni M., Haisma H.J., Maarsingh H., Dekker F.J. Histone acetyltransferases are crucial regulators in NF-kappaB mediated inflammation. Drug Discov. Today 2011, 16:504-511.
15. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
16. Hahn H., Park Y.S., Ha I.S., Cheong H.I., Choi Y. Age-related differences in adriamycin-induced nephropathy. Pediatr. Nephrol. 2004, 19:761-766.
17. Imai N., Hishikawa K., Marumo T., Hirahashi J., Inowa T., Matsuzaki Y., Okano H., Kitamura T., Salant D., Fujita T. Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury. Stem Cells 2007, 25:2469-2475.
18. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
19. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
20. Kiernan R., Bres V., Ng R.W., Coudart M.P., El Messaoudi S., Sardet C., Jin D.Y., Emiliani S., Benkirane M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 2003, 278:2758-2766.
21. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3:166-179.
22. Kinugasa F., Noto T., Matsuoka H., Urano Y., Sudo Y., Takakura S., Mutoh S. Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl. Immunol. 2010, 23:18-23.
23. Kramer O.H., Baus D., Knauer S.K., Stein S., Jager E., Stauber R.H., Grez M., Pfitzner E., Heinzel T. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006, 20:473-485.
24. Kriz W., Gretz N., Lemley K.V. Progression of glomerular diseases: is the podocyte the culprit?. Kidney Int. 1998, 54:687-697.
25. Lagace D.C., O'Brien T., Gurvich N., Nachtigal M.W., Klein P.S. Valproic acid: how it works. Or not. Clin. Neurosci. Res. 2004, 4:215-225.
26. Lee V.W., Harris D.C. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011, 16:30-38.
27. Mannaerts I., Nuytten N.R., Rogiers V., Vanderkerken K., van Grunsven L.A., Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 2010, 51:603-614.
28. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 2009, 107:600-608.
29. Marumo T., Hishikawa K., Yoshikawa M., Hirahashi J., Kawachi S., Fujita T. Histone deacetylase modulates the proinflammatory and fibrotic changes in tubulointerstitial injury. Am. J. Physiol. Renal Physiol. 2010, 298:F133-F141.
30. McKinsey T.A. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol. Med. 2011, 17:434-441.
31. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 2003, 111:539-552.
32. Noh H., Oh E.Y., Seo J.Y., Yu M.R., Kim Y.O., Ha H., Lee H.B. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am. J. Physiol. Renal Physiol. 2009, 297:F729-F739.
33. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 2012, 52:1213-1225.
34. Okuda S., Oh Y., Tsuruda H., Onoyama K., Fujimi S., Fujishima M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int. 1986, 29:502-510.
35. Pang M., Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J. Pharmacol. Exp. Ther. 2010, 335:266-272.
36. Pang M., Kothapally J., Mao H., Tolbert E., Ponnusamy M., Chin Y.E., Zhuang S. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. Renal Physiol. 2009, 297:F996-F1005.
37. Pang M., Ma L., Liu N., Ponnusamy M., Zhao T.C., Yan H., Zhuang S. Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins. J. Cell. Biochem. 2011, 112:2138-2148.
38. Peltier J., Bellocq A., Perez J., Doublier S., Dubois Y.C., Haymann J.P., Camussi G., Baud L. Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. J. Am. Soc. Nephrol. 2006, 17:3415-3423.
39. Pippin J.W., Brinkkoetter P.T., Cormack-Aboud F.C., Durvasula R.V., Hauser P.V., Kowalewska J., Krofft R.D., Logar C.M., Marshall C.B., Ohse T., Shankland S.J. Inducible rodent models of acquired podocyte diseases. Am. J. Physiol. Renal Physiol. 2009, 296:F213-F229.
40. Rangan G.K., Wang Y., Tay Y.C., Harris D.C. Cytokine gene expression in Adriamycin nephropathy: effects of antioxidant nuclear factor kappaB inhibitors in established disease. Nephron 2000, 86:482-490.
41. Sakemi T., Ohtsuka N., Tomiyoshi Y., Morito F. Sex difference in progression of adriamycin-induced nephropathy in rats. Am. J. Nephrol. 1996, 16:540-547.
42. Sakemi T., Ohtsuka N., Tomiyoshi Y., Morito F. The ovaries attenuate the aggravating effect of testosterone on glomerular injury in Adriamycin-induced nephropathy of female rats. Kidney Blood Press. Res. 1997, 20:44-50.
43. Sanderson L., Taylor G.W., Aboagye E.O., Alao J.P., Latigo J.R., Coombes R.C., Vigushin D.M. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metab. Dispos. 2004, 32:1132-1138.
44. Schieppati A., Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. Suppl. 2005, S7-S10.
45. Shankland S.J., Pippin J.W., Reiser J., Mundel P. Podocytes in culture: past, present, and future. Kidney Int. 2007, 72:26-36.
46. Shuttleworth S.J., Bailey S.G., Townsend P.A. Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr. Drug Targets 2010, 11:1430-1438.
47. Van Beneden K., van Grunsven L.A., Geers C., Pauwels M., Desmouliere A., Verbeelen D., Geerts A., Van Den Branden C. CRBP-I in the renal tubulointerstitial compartment of healthy rats and rats with renal fibrosis. Nephrol. Dial. Transplant. 2008, 23:3464-3471.
48. Van Beneden K., Geers C., Pauwels M., Mannaerts I., Verbeelen D., van Grunsven L.A., Van Den Branden C. Valproic acid attenuates proteinuria and kidney injury. J. Am. Soc. Nephrol. 2011, 22:1863-1875.
49. Van Beneden K., Mannaerts I., Pauwels M., Van Den Branden C., van Grunsven L.A. HDAC inhibitors in experimental liver and kidney fibrosis. Fibrogenesis Tissue Repair 2013, 6:1.
50. Van Den Branden C., Deman A., Ceyssens B., Pauwels M., Empsen C., Verbeelen D. Vitamin E protects renal antioxidant enzymes and attenuates glomerulosclerosis in Adriamycin-treated rats. Nephron 2002, 91:129-133.
51. Vielhauer V., Berning E., Eis V., Kretzler M., Segerer S., Strutz F., Horuk R., Grone H.J., Schlondorff D., Anders H.J. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int. 2004, 66:2264-2278.
52. Wang Y., Wang Y.P., Tay Y.C., Harris D.C. Progressive Adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000, 58:1797-1804.
53. Xia Q., Sung J., Chowdhury W., Chen C.L., Hoti N., Shabbeer S., Carducci M., Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006, 66:7237-7244.
54. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
55. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265:17174-17179.
56. Yoshikawa M., Hishikawa K., Marumo T., Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J. Am. Soc. Nephrol. 2007, 18:58-65.
57. Yu Z., Kone B.C. Targeted histone H4 acetylation via phosphoinositide 3-kinase- and p70s6-kinase-dependent pathways inhibits iNOS induction in mesangial cells. Am. J. Physiol. Renal Physiol. 2006, 290:F496-F502.
58. Zhang Y.W., Shi J., Li Y.J., Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp. (Warsz.) 2009, 57:435-445.
59. Zheng Z., Schmidt-Ott K.M., Chua S., Foster K.A., Frankel R.Z., Pavlidis P., Barasch J., D'Agati V.D., Gharavi A.G. A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2502-2507.
60. Zheng Z., Pavlidis P., Chua S., D'Agati V.D., Gharavi A.G. An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse. J. Am. Soc. Nephrol. 2006, 17:1796-1800.